USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 29, 2025 /PRNewswire/ -- USA News Group News Commentary – As the new administration starts to make its mark in the United States, President Trump recently announced a $500 billion AI infrastructure investment in the country, which could have major ramifications on the standard of living of Americans and the world. Healthcare industry leaders are rapidly adopting artificial intelligence (AI) tech into their operatio ...

Moderna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere, the Dow saw an upswing of 0.65%, while the tech-heavy Nasdaq depreciated by 3.07%.Prior to today's trading, shares of the biotechnology company had gained 3.19% over the past month. This has outpaced the Medical sector's gain of 1.84% and the S&P 500's gain of 1.08% in that time.Market participants will be cl ...

Are you ready for artificial intelligence (AI)-driven mRNA vaccines?Shares of Moderna (MRNA -2.31%) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence.The maker of vaccines, including the mRNA vaccine for COVID-19, is amid a 90% stock price downturn. In fact, the share price is now only right around the same level as it was before the 2020 pandemic. However, this week, the company got good news with a mention of mRNA vaccines at the Project Stargate announcement ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (MRNA -2.31%) as a biotech that'll never recover its former glory -- which it built on the success of its coronavirus vaccine program. But where there are widespread bearish sentiments about a stock, there's also often an opportunity for investors who are willing to focus on the long term and appreciate that things won't always be like they are now.In that vein, let's learn about the three most important things you sh ...

Core Insights - Moderna is developing a vaccine for norovirus, with a large phase three trial currently underway, and results expected as early as late 2024 or 2026 [2][10] - The current winter has seen a significant increase in norovirus cases, with a 36% rise in outbreaks compared to the previous season, and twice as many positive tests reported in January [4][3] - The vaccine candidate targets three genotypes of norovirus, but does not include the genotype responsible for most infections this year [5][6] Company Strategy - The primary goal of the vaccine is not to completely prevent norovirus but to reduce the severity of symptoms and prevent hospital visits [7] - The company aims to vaccinate vulnerable populations, particularly seniors aged 65 and above, who are at higher risk of complications from norovirus [8] - Other target groups include healthcare workers, daycare workers, and individuals on cruise ships, as these populations are frequently exposed to norovirus [9][10] Market Considerations - Investors are skeptical about the commercial viability of the vaccine, contingent on its effectiveness, with a focus on protecting those in nursing homes and cruise passengers [10] - The vaccine is not currently being tested in children, but if successful in adults, further studies in children will be necessary [10]

Tuesday, Moderna Inc MRNA stock is trading higher with a session volume of 8.0 million as per data from Benzinga Pro.On Friday, Moderna announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines.The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Pre ...

Moderna's Vaccine Development - Moderna received a $590 million grant from the U S Department of Health and Human Services to accelerate the development of mRNA-based pandemic influenza vaccines, including mRNA-1018 [1][5] - The company initiated Phase 1/2 testing of mRNA-1018 in 2023, targeting healthy adults aged 18 and above, with positive preliminary results leading to the launch of a Phase 3 study [2][5] Bird Flu Impact and Market Response - The Centers for Disease Control and Prevention (CDC) reported widespread bird flu in wild birds and outbreaks in poultry and U S dairy cows, with several human cases among dairy and poultry workers [3] - Cal-Maine Foods, the largest U S egg producer, noted rising egg prices due to production limits caused by the bird flu outbreak [4] - Despite a 5% increase in Moderna's stock price, shares remain nearly 65% lower over the past year due to declining COVID-19 vaccine sales [4]

Moderna Inc (NASDAQ:MRNA) stock is surging today, up 8.7% at $37.02 at last glance, after the vaccine maker was awarded $590 million from the U.S. Health and Human Services Department to speed up the development of its bird flu vaccine, as the virus spreads rapidly throughout the country. MRNA has had a rough go of it since its meteoric rise at the height of Covid-19, as the demand vaccines waned. Just last week, the stock plummeted to its lowest levels since 2020 after a slashed forecast. Since last Januar ...

Core Viewpoint - Moderna is transitioning from a focus on its coronavirus vaccine to a more traditional pharmaceutical business model, with expectations of launching new products and managing financial constraints in the coming years [1][3][12] Group 1: Financial Outlook - Moderna's trailing-12-month revenue is over $5 billion, with reported operating losses of $2.7 billion, indicating financial pressure to produce in-demand medicines [5] - The company plans to reduce its annual research and development investment by $1.1 billion by 2027, reflecting a shift in financial strategy [4] Group 2: Product Pipeline and Potential - Moderna aims to launch a total of 10 products over the next three years, with key candidates including a combination shot for influenza and COVID, an influenza vaccine, and a next-generation COVID vaccine, each potentially generating over $1 billion in annual sales [4][6] - The Department of Health and Human Services has committed $590 million to support Moderna's pandemic influenza vaccine program, which may enter late-stage trials soon, reducing risks associated with advancing additional pipeline programs [7] Group 3: Oncology and Future Growth - Moderna is developing seven oncology drugs in mid-to-late-stage clinical trials, particularly focusing on individualized neoantigen therapies (INTs) that leverage the genetic sequence of tumor cells to enhance immune response against cancer [9][10] - Successful commercialization of any oncology candidates could signal a positive future for the company, even if immediate revenue inflow is limited due to the niche markets targeted [10][11] Group 4: Investment Horizon - Investors should be prepared for a long-term investment, with expectations of significant growth materializing around early 2028, rather than in the immediate future [12][13] - The company must demonstrate the viability of its clinical programs within the next three years to maintain investor confidence and stock value [15]

Funding and Development - Moderna received $590 million from the U.S. government through BARDA to accelerate the development of an mRNA-based vaccine targeting the H5N1 virus (bird flu) [1] - The funding will support the late-stage development of mRNA-1018, Moderna's investigational pandemic influenza vaccine against H5 and H7 avian influenza viruses [2] - The funds will also help expand clinical studies for up to five additional pandemic influenza subtypes [2] - This is the second time in less than a year that Moderna has secured U.S. government funding for its bird flu vaccine, following a $176 million award in July [4] Clinical Progress - Moderna initiated a phase I/II study for mRNA-1018 in 2023 in healthy adults [3] - Positive preliminary data from the phase I/II study has prompted the company to advance the vaccine to late-stage development [3] - Moderna plans to share data from the phase I/II study at a future medical meeting [3] Market and Industry Context - The U.S. CDC confirmed the first human death from the H5N1 virus earlier this month, with 67 human cases reported since the beginning of last year [5] - mRNA-based vaccines offer faster development and manufacturing scalability compared to traditional vaccines, a key advantage highlighted by BARDA [7] - Moderna's stock rose nearly 5% in after-market trading following the funding announcement, despite a 66% decline over the past year [6][7] Competitive Landscape - Moderna is not the only company working with BARDA on bird flu vaccines; CSL Seqirus has a deal for 150 million doses of its protein-based H5N1 vaccine and received a $34 million award in October [9] - CureVac is developing an mRNA-based bird flu vaccine in collaboration with GSK, currently in phase I/II studies [10] - Novavax is also developing a bird flu vaccine using a new approach, currently in preclinical studies [10]